Drug intelligence / Profile preview

CpG oligoDNA

Development stage
Unknown
Lead developer
Dynavax Technologies
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intramuscular, Subcutaneous, Intratumoral
01

Overview

CpG oligoDNA, also known as CpG oligodeoxynucleotides (CpG ODNs), is a class of synthetic, short, single-stranded DNA molecules containing unmethylated cytosine-guanine (CpG) dinucleotide motifs. These motifs mimic the DNA found in bacteria and viruses, serving as potent agonists of Toll-like Receptor 9 (TLR9). Activation of TLR9 by CpG ODNs triggers innate and adaptive immune responses, including the activation of B cells, plasmacytoid dendritic cells, NK cells, and cytotoxic T lymphocytes. They are primarily investigated as vaccine adjuvants and anticancer immunotherapies for various indications, including glioblastoma, mesothelioma, and infectious diseases. While several specific CpG ODNs (e.g., CpG 1018, CpG 7909) have been developed by different companies, CpG oligoDNA itself refers to the broader class of these nucleic acid therapeutics.

Other names
CpG oligodeoxynucleotidesCpG DNAunmethylated CpG dinucleotidesCpG oligonucleotides
02

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on CpG oligoDNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CpG oligoDNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call